RCHY1抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-4: 293T, A549, Jurkat, 231 cell lysates, Primary antibody: P00627(RCHY1 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P00627(RCHY1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The RCHY1 antibody targets the RCHY1 protein, also known as PIRH2 (p53-induced RING-H2 protein), a member of the RING finger family of E3 ubiquitin ligases. RCHY1 plays a critical role in regulating protein degradation via the ubiquitin-proteasome system, particularly in cell cycle control, apoptosis, and DNA damage response. It interacts with and ubiquitinates several key substrates, including the tumor suppressor p53. promoting its proteasomal degradation, thereby linking RCHY1 to oncogenic processes. Overexpression of RCHY1 has been observed in various cancers, correlating with poor prognosis due to reduced p53 activity.

Structurally, RCHY1 contains a C-terminal RING domain essential for its E3 ligase activity and an N-terminal nuclear localization signal. Its expression is transcriptionally induced by p53. forming a negative feedback loop to modulate p53 levels post-stress. Dysregulation of this pathway is implicated in tumorigenesis and chemoresistance.

RCHY1 antibodies are widely used in research to study protein interactions, expression patterns, and subcellular localization in cancer models. They are critical tools for Western blotting, immunoprecipitation, and immunohistochemistry, aiding in the exploration of RCHY1's role in cellular homeostasis and disease. Recent studies also investigate RCHY1 inhibitors as potential therapeutic agents to restore p53 function in cancers.